400 likes | 1.1k Views
Drugs Used in H yperlipidemia. By Dr. Sasan Zaeri PharmD , PhD. Introduction. Cholesterol Serves as a component of cell membranes and intracellular organelle membranes Is involved in the synthesis of certain hormones including estrogen, progesterone, testosterone, adrenal corticosteroids
E N D
Drugs Used in Hyperlipidemia By Dr. SasanZaeri PharmD, PhD
Introduction • Cholesterol • Serves as a component of cell membranes and intracellular organelle membranes • Is involved in the synthesis of certain hormones including estrogen, progesterone, testosterone, adrenal corticosteroids • Needed for the synthesis of bile salts which are needed for digestion and absorption of fats
Origin of cholesterol • Liver • Acetyl CoA is converted to mevalonic acid and ultimately to cholesterol by HydroxyMethylGlutaryl Coenzyme A (HMG-CoA) reductase • Endogenous synthesis of cholesterol increases at night
Lipoproteins • Serve as carriers for transporting lipids (cholesterol and triglycerides) in the blood
Apolipoproteins • Embedded in the lipoprotein shell • Three functions • Serve as recognition sites for cell-surface receptors; allowing cells to bind and ingest the lipoprotein • Activate enzymes that will metabolize the lipoprotein • ↑ structural stability of the lipoprotein
Types of lipoproteins
Types of lipoproteins
VLDL (very low density lipoprotein) • Contain triglycerides (TGs) and some cholesterol • Account for nearly all TGs in the blood • Contain Apo B-100 • Deliver triglycerides from the liver to adipose tissues and muscles
LDL (low density lipoprotein) • “Bad cholesterol” • Contains cholesterol • Accounts for 60-70% of cholesterol in the blood • Contains Apo B-100 • Delivers cholesterol to peripheral tissues • Makes the greatest contribution to coronary atherosclerosis • Oxidized LDL contributes to atherosclerotic plaque
HDL (high-density lipoprotein) • “Good cholesterol” • Contain cholesterol • Account for 20-30% of cholesterol in the blood • Some contain Apo A-I and Apo A-II • Apo A-I is cardioprotective • Transports cholesterol from the peripheral tissues back to the liver – promotes cholesterol removal • Antiatherogenic
Why to Treat Hyperlipidemia To prevent or slow progression of atherosclerosis To reduce the risk of coronary artery disease To prolong life
Treatment of hyperlipidemia • Non-Pharmacological Therapy – first line treatment • Diet modification • Decrease intake of total fat and especially saturated fat • Increase fiber intake • Increase Omega-3-fatty acids (found in fish) • ↑ fruits and vegetables (antioxidants) • ↓ simple sugars (sucrose) • Exercise (↑ HDL levels) • Pharmacological Therapy
Treatment of hyperlipidemia • Drug therapy • HMG-CoA Reductase Inhibitors (Statins) • Bile Acid-binding Resins (e.g. Cholestyramine, Cholestipol) • Inhibitors of cholesterol absorption (Ezetimibe) • Niacin (Nicotinic Acid) • Fibric Acid Derivatives (e.g. Gemfibrozil)
Statins (Atorvastatin, Lovastatin, Fluvastatin, Simvastatin etc.) • MOA • Inhibits hepatic HMG CoA reductase >>> Inhibition of cholesterol synthesis causes hepatocytes to synthesize more LDL receptors >>>Hepatocytes will remove more LDLs from the blood • Most Effective for ↓ LDL-C • Decrease production of apolipoprotein B-100, thereby ↓ production of VLDL • ↓ Plaque cholesterol content and ↓ inflammation at the plaque site (Anti-atherosclorotic properties)
STATINS: effects on lipoproteins LDL-C: 20-55% TG: 7-45% (for TG>250 mg/dL, the percent is same as that of LDL; for TG<250 mg/dL maximum 25% reduction) HDL-C: 5-15%
Statins-Indication: • Used in hypercholesterolemia • Atorvastatin is most efficacious agent for use in severe hypercholesterolemia (>40-50% LDL-C lowering) • ↓ LDL within 2 weeks; max reduction in 4-6 weeks • Used in Coronary Artery Disease (CAD) • Clinical trials have shown that they reduce mortality in patients with ischemic heart disease • Used in patients with triglycerides levels higher than 250 mg/dLand with reduced HDL-C levels
Some Points about Statins • Statins have high first pass extraction by liver • Prodrugs – lovastatin and simvastatin • Statins have greatest efficacy when taken at night • Atorvastatin has the longest half-life • Tolerated best among other hypolipemic drugs
Statins – Adverse Effects • Rash • GI disturbances (dyspepsia, cramps, flatulence, constipation, abdominal pain) • Hepatotoxicity • Myopathy (myositis and rhabdomyolysis) • Risk highest especially in combination with fibrates • Cyp450 3A4 drug interactions • Statins are pregnancy category X
Bile Acid-Binding Resins (Cholestyramine and Colestipol) • MOA • Binding to bile acids (the metabolites of cholesterol) in the intestinal lumen and inhibition from their reabsorption >>> ↑ LDL receptors by liver cells to capture more cholesterol and synthesize bile acids
Bile-acid binding resins- Indications • Used in hypercholesterolemia (↓ LDL-C 15-20%) • Normally used as adjuncts to the statins to ↓ LDL-C (by 50%) • Can be used to relieve pruritisin patients with cholestasis • Can be used for severe digitalis toxicity • Available in powder form (must be mixed with fluid) • Must be taken with meals
Bile Acid-Binding Resins- Adverse Effects and Drug Interactions • GI discomfort: (bloating, dyspepsia, nausea, constipation) • Large doses may impair absorption of fats or fat soluble vitamins (A, D, E, and K) • Resins bind many drugs e.g. digoxin, warfarin, tetracycline, thyroxineetc. • These agents should be given either 1 hour before or 4 hours after the resins
Inhibitors of cholesterol absorption (Ezetimibe) • MOA: Prevention of absorption of dietary cholesterol and cholesterol that is excreted in bile >>>↑LDL receptors in liver and ↑removal of LDL-C from the blood
Ezetimibe- Indication • Used in hypercholesterolemia • As monotherapy, ezetimibe reduces LDL-C by about 18% • When combined with a statin, it is even more effective • Ezetimibe is well tolerated
MOA of Niacin (Nicotinic acid) • Inhibits VLDL secretion into the blood thereby preventing production of LDL • Increases clearance of VLDL via lipoprotein lipase pathway • Inhibits FFA release from adipose tissues by inhibiting the intracellular lipase system • Decreases HDLcatabolic rate
NICOTINIC ACID: effects on lipoproteins LDL-C: 5-25 %; TG: 20-50 % HDL-C: 15-35 %
Niacin- Indications • Hypertriglyceridemia • Mixed elevation of LDL-C and TG (in combination with statins) • Elevation of TG (VLDL) and low levels of HDL • Start with low dose and gradually increase
Niacin - Adverse effects • Flushing • Prostaglandin-mediated • Occurs after drug is started or ↑ dose • Lasts for the first several weeks • 325mg aspirin 30 minutes before morning dose prevents prostaglandin synthesis • Nausea and abdominal discomfort • Hyperuricemia, hepatotoxicity • Niacin is NOT well-tolerated
Fibrates (Gemfibrozil, Fenofibrate, Clofibrate) • Little or no effect on LDL, ↓VLDL (TG), moderate ↑ of HDL • MOA: Activation of Peroxisome Proliferator-Activated Receptor-α (PPAR- α) • ↑ Activity of endothelial lipoprotein lipase • ↑ FFA oxidation in hepatocytes • ↓ Secretion of VLDL by liver • ↑ HDL levels moderately by ↑ Apo AI and Apo AII
Fibrates - Indications • Hypertriglyceridemia • Mixed elevation of LDL-C and TG (in combination with statins)
Fibrates - Adverse Effects • Nausea (most prevalent) • Rashes (prevalent) • Cholesterol gallstones (Gemfibrozil) • Use with caution in patients with biliary tract dx, women, obese people • Myopathy (muscle injury) • Will increase risk of statin-induced myopathy when used together